Global Respiratory Antivirals 麻豆原创 2024 by Company, Regions, Type and Application, Forecast to 2030

Publication ID:

GIR122405105

Publication Date:

December 12, 2024

Pages:

117

Publisher:

GIR

Countries:

Global [1]

USD 3,480.00

Pharmaceutical Manufacturing [2]

Healthcare [3]

Pharma & Healthcare [4]

Description:

The global Respiratory Antivirals market size was valued at USD million in 2023 and is forecast to a readjusted size of USD million by 2030 with a CAGR of % during review period.
The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during the next six years. The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, the chemical drug market is estimated to increase from 1005 billion in 2018 to 1094 billion U.S. dollars in 2022. The pharmaceutical market factors such as increasing demand for healthcare, technological advancements, and the rising prevalence of chronic diseases, increase in funding from private & government organizations for development of pharmaceutical manufacturing segments and rise in R&D activities for drugs. However, the industry also faces challenges such as stringent regulations, high costs of research and development, and patent expirations. Companies need to continuously innovate and adapt to these challenges to stay competitive in the market and ensure their products reach patients in need. Additionally, the COVID-19 pandemic has highlighted the importance of vaccine development and supply chain management, further emphasizing the need for pharmaceutical companies to be agile and responsive to emerging public health needs.
The report includes an overview of the development of the Respiratory Antivirals industry chain, the market status of Upper Respiratory Tract Infections (URTIs) (Nucleoside Analogs, Neuraminidase Inhibitors), Influenza (Nucleoside Analogs, Neuraminidase Inhibitors), and key enterprises in developed and developing market, and analysed the cutting-edge technology, patent, hot applications and market trends of Respiratory Antivirals.
Regionally, the report analyzes the Respiratory Antivirals markets in key regions. North America and Europe are experiencing steady growth, driven by government initiatives and increasing consumer awareness. Asia-Pacific, particularly China, leads the global Respiratory Antivirals market, with robust domestic demand, supportive policies, and a strong manufacturing base.
Key Features:
The report presents comprehensive understanding of the Respiratory Antivirals market. It provides a holistic view of the industry, as well as detailed insights into individual components and stakeholders. The report analysis market dynamics, trends, challenges, and opportunities within the Respiratory Antivirals industry.
The report involves analyzing the market at a macro level:
麻豆原创 Sizing and Segmentation: Report collect data on the overall market size, including the revenue generated, and market share of different by Type (e.g., Nucleoside Analogs, Neuraminidase Inhibitors).
Industry Analysis: Report analyse the broader industry trends, such as government policies and regulations, technological advancements, consumer preferences, and market dynamics. This analysis helps in understanding the key drivers and challenges influencing the Respiratory Antivirals market.
Regional Analysis: The report involves examining the Respiratory Antivirals market at a regional or national level. Report analyses regional factors such as government incentives, infrastructure development, economic conditions, and consumer behaviour to identify variations and opportunities within different markets.
麻豆原创 Projections: Report covers the gathered data and analysis to make future projections and forecasts for the Respiratory Antivirals market. This may include estimating market growth rates, predicting market demand, and identifying emerging trends.
The report also involves a more granular approach to Respiratory Antivirals:
Company Analysis: Report covers individual Respiratory Antivirals players, suppliers, and other relevant industry players. This analysis includes studying their financial performance, market positioning, product portfolios, partnerships, and strategies.
Consumer Analysis: Report covers data on consumer behaviour, preferences, and attitudes towards Respiratory Antivirals This may involve surveys, interviews, and analysis of consumer reviews and feedback from different by Application (Upper Respiratory Tract Infections (URTIs), Influenza).
Technology Analysis: Report covers specific technologies relevant to Respiratory Antivirals. It assesses the current state, advancements, and potential future developments in Respiratory Antivirals areas.
Competitive Landscape: By analyzing individual companies, suppliers, and consumers, the report present insights into the competitive landscape of the Respiratory Antivirals market. This analysis helps understand market share, competitive advantages, and potential areas for differentiation among industry players.
麻豆原创 Validation: The report involves validating findings and projections through primary research, such as surveys, interviews, and focus groups.
麻豆原创 Segmentation
Respiratory Antivirals market is split by Type and by Application. For the period 2019-2030, the growth among segments provides accurate calculations and forecasts for consumption value by Type, and by Application in terms of value.
麻豆原创 segment by Type
Nucleoside Analogs
Neuraminidase Inhibitors
Ion Channel Blockers
Fusion Protein Inhibitors
麻豆原创 segment by Application
Upper Respiratory Tract Infections (URTIs)
Influenza
Bronchiolitis
Pneumonia
Measles
Others
麻豆原创 segment by players, this report covers
GSK
Boehringer Ingelheim
AstraZeneca
Merck
Novartis
Beximco Pharmaceuticals
Pfizer
Roche
Bristol-Myers Squibb Company
Johnson & Johnson
AbbVie Inc.
Sanofi
麻豆原创 segment by regions, regional analysis covers
North America (United States, Canada, and Mexico)
Europe (Germany, France, UK, Russia, Italy, and Rest of Europe)
Asia-Pacific (China, Japan, South Korea, India, Southeast Asia, Australia and Rest of Asia-Pacific)
South America (Brazil, Argentina and Rest of South America)
Middle East & Africa (Turkey, Saudi Arabia, UAE, Rest of Middle East & Africa)
The content of the study subjects, includes a total of 13 chapters:
Chapter 1, to describe Respiratory Antivirals product scope, market overview, market estimation caveats and base year.
Chapter 2, to profile the top players of Respiratory Antivirals, with revenue, gross margin and global market share of Respiratory Antivirals from 2019 to 2024.
Chapter 3, the Respiratory Antivirals competitive situation, revenue and global market share of top players are analyzed emphatically by landscape contrast.
Chapter 4 and 5, to segment the market size by Type and application, with consumption value and growth rate by Type, application, from 2019 to 2030.
Chapter 6, 7, 8, 9, and 10, to break the market size data at the country level, with revenue and market share for key countries in the world, from 2019 to 2024.and Respiratory Antivirals market forecast, by regions, type and application, with consumption value, from 2025 to 2030.
Chapter 11, market dynamics, drivers, restraints, trends and Porters Five Forces analysis.
Chapter 12, the key raw materials and key suppliers, and industry chain of Respiratory Antivirals.
Chapter 13, to describe Respiratory Antivirals research findings and conclusion.

Please Note - This is an on demand report and will be delivered in 2 business days (48 Hours) post payment.

Table Of Contents:

1 麻豆原创 Overview
1.1 Product Overview and Scope of Respiratory Antivirals
1.2 麻豆原创 Estimation Caveats and Base Year
1.3 Classification of Respiratory Antivirals by Type
1.3.1 Overview: Global Respiratory Antivirals 麻豆原创 Size by Type: 2019 Versus 2023 Versus 2030
1.3.2 Global Respiratory Antivirals Consumption Value 麻豆原创 Share by Type in 2023
1.3.3 Nucleoside Analogs
1.3.4 Neuraminidase Inhibitors
1.3.5 Ion Channel Blockers
1.3.6 Fusion Protein Inhibitors
1.4 Global Respiratory Antivirals 麻豆原创 by Application
1.4.1 Overview: Global Respiratory Antivirals 麻豆原创 Size by Application: 2019 Versus 2023 Versus 2030
1.4.2 Upper Respiratory Tract Infections (URTIs)
1.4.3 Influenza
1.4.4 Bronchiolitis
1.4.5 Pneumonia
1.4.6 Measles
1.4.7 Others
1.5 Global Respiratory Antivirals 麻豆原创 Size & Forecast
1.6 Global Respiratory Antivirals 麻豆原创 Size and Forecast by Region
1.6.1 Global Respiratory Antivirals 麻豆原创 Size by Region: 2019 VS 2023 VS 2030
1.6.2 Global Respiratory Antivirals 麻豆原创 Size by Region, (2019-2030)
1.6.3 North America Respiratory Antivirals 麻豆原创 Size and Prospect (2019-2030)
1.6.4 Europe Respiratory Antivirals 麻豆原创 Size and Prospect (2019-2030)
1.6.5 Asia-Pacific Respiratory Antivirals 麻豆原创 Size and Prospect (2019-2030)
1.6.6 South America Respiratory Antivirals 麻豆原创 Size and Prospect (2019-2030)
1.6.7 Middle East and Africa Respiratory Antivirals 麻豆原创 Size and Prospect (2019-2030)
2 Company Profiles
2.1 GSK
2.1.1 GSK Details
2.1.2 GSK Major Business
2.1.3 GSK Respiratory Antivirals Product and Solutions
2.1.4 GSK Respiratory Antivirals Revenue, Gross Margin and 麻豆原创 Share (2019-2024)
2.1.5 GSK Recent Developments and Future Plans
2.2 Boehringer Ingelheim
2.2.1 Boehringer Ingelheim Details
2.2.2 Boehringer Ingelheim Major Business
2.2.3 Boehringer Ingelheim Respiratory Antivirals Product and Solutions
2.2.4 Boehringer Ingelheim Respiratory Antivirals Revenue, Gross Margin and 麻豆原创 Share (2019-2024)
2.2.5 Boehringer Ingelheim Recent Developments and Future Plans
2.3 AstraZeneca
2.3.1 AstraZeneca Details
2.3.2 AstraZeneca Major Business
2.3.3 AstraZeneca Respiratory Antivirals Product and Solutions
2.3.4 AstraZeneca Respiratory Antivirals Revenue, Gross Margin and 麻豆原创 Share (2019-2024)
2.3.5 AstraZeneca Recent Developments and Future Plans
2.4 Merck
2.4.1 Merck Details
2.4.2 Merck Major Business
2.4.3 Merck Respiratory Antivirals Product and Solutions
2.4.4 Merck Respiratory Antivirals Revenue, Gross Margin and 麻豆原创 Share (2019-2024)
2.4.5 Merck Recent Developments and Future Plans
2.5 Novartis
2.5.1 Novartis Details
2.5.2 Novartis Major Business
2.5.3 Novartis Respiratory Antivirals Product and Solutions
2.5.4 Novartis Respiratory Antivirals Revenue, Gross Margin and 麻豆原创 Share (2019-2024)
2.5.5 Novartis Recent Developments and Future Plans
2.6 Beximco Pharmaceuticals
2.6.1 Beximco Pharmaceuticals Details
2.6.2 Beximco Pharmaceuticals Major Business
2.6.3 Beximco Pharmaceuticals Respiratory Antivirals Product and Solutions
2.6.4 Beximco Pharmaceuticals Respiratory Antivirals Revenue, Gross Margin and 麻豆原创 Share (2019-2024)
2.6.5 Beximco Pharmaceuticals Recent Developments and Future Plans
2.7 Pfizer
2.7.1 Pfizer Details
2.7.2 Pfizer Major Business
2.7.3 Pfizer Respiratory Antivirals Product and Solutions
2.7.4 Pfizer Respiratory Antivirals Revenue, Gross Margin and 麻豆原创 Share (2019-2024)
2.7.5 Pfizer Recent Developments and Future Plans
2.8 Roche
2.8.1 Roche Details
2.8.2 Roche Major Business
2.8.3 Roche Respiratory Antivirals Product and Solutions
2.8.4 Roche Respiratory Antivirals Revenue, Gross Margin and 麻豆原创 Share (2019-2024)
2.8.5 Roche Recent Developments and Future Plans
2.9 Bristol-Myers Squibb Company
2.9.1 Bristol-Myers Squibb Company Details
2.9.2 Bristol-Myers Squibb Company Major Business
2.9.3 Bristol-Myers Squibb Company Respiratory Antivirals Product and Solutions
2.9.4 Bristol-Myers Squibb Company Respiratory Antivirals Revenue, Gross Margin and 麻豆原创 Share (2019-2024)
2.9.5 Bristol-Myers Squibb Company Recent Developments and Future Plans
2.10 Johnson & Johnson
2.10.1 Johnson & Johnson Details
2.10.2 Johnson & Johnson Major Business
2.10.3 Johnson & Johnson Respiratory Antivirals Product and Solutions
2.10.4 Johnson & Johnson Respiratory Antivirals Revenue, Gross Margin and 麻豆原创 Share (2019-2024)
2.10.5 Johnson & Johnson Recent Developments and Future Plans
2.11 AbbVie Inc.
2.11.1 AbbVie Inc. Details
2.11.2 AbbVie Inc. Major Business
2.11.3 AbbVie Inc. Respiratory Antivirals Product and Solutions
2.11.4 AbbVie Inc. Respiratory Antivirals Revenue, Gross Margin and 麻豆原创 Share (2019-2024)
2.11.5 AbbVie Inc. Recent Developments and Future Plans
2.12 Sanofi
2.12.1 Sanofi Details
2.12.2 Sanofi Major Business
2.12.3 Sanofi Respiratory Antivirals Product and Solutions
2.12.4 Sanofi Respiratory Antivirals Revenue, Gross Margin and 麻豆原创 Share (2019-2024)
2.12.5 Sanofi Recent Developments and Future Plans
3 麻豆原创 Competition, by Players
3.1 Global Respiratory Antivirals Revenue and Share by Players (2019-2024)
3.2 麻豆原创 Share Analysis (2023)
3.2.1 麻豆原创 Share of Respiratory Antivirals by Company Revenue
3.2.2 Top 3 Respiratory Antivirals Players 麻豆原创 Share in 2023
3.2.3 Top 6 Respiratory Antivirals Players 麻豆原创 Share in 2023
3.3 Respiratory Antivirals 麻豆原创: Overall Company Footprint Analysis
3.3.1 Respiratory Antivirals 麻豆原创: Region Footprint
3.3.2 Respiratory Antivirals 麻豆原创: Company Product Type Footprint
3.3.3 Respiratory Antivirals 麻豆原创: Company Product Application Footprint
3.4 New 麻豆原创 Entrants and Barriers to 麻豆原创 Entry
3.5 Mergers, Acquisition, Agreements, and Collaborations
4 麻豆原创 Size Segment by Type
4.1 Global Respiratory Antivirals Consumption Value and 麻豆原创 Share by Type (2019-2024)
4.2 Global Respiratory Antivirals 麻豆原创 Forecast by Type (2025-2030)
5 麻豆原创 Size Segment by Application
5.1 Global Respiratory Antivirals Consumption Value 麻豆原创 Share by Application (2019-2024)
5.2 Global Respiratory Antivirals 麻豆原创 Forecast by Application (2025-2030)
6 North America
6.1 North America Respiratory Antivirals Consumption Value by Type (2019-2030)
6.2 North America Respiratory Antivirals Consumption Value by Application (2019-2030)
6.3 North America Respiratory Antivirals 麻豆原创 Size by Country
6.3.1 North America Respiratory Antivirals Consumption Value by Country (2019-2030)
6.3.2 United States Respiratory Antivirals 麻豆原创 Size and Forecast (2019-2030)
6.3.3 Canada Respiratory Antivirals 麻豆原创 Size and Forecast (2019-2030)
6.3.4 Mexico Respiratory Antivirals 麻豆原创 Size and Forecast (2019-2030)
7 Europe
7.1 Europe Respiratory Antivirals Consumption Value by Type (2019-2030)
7.2 Europe Respiratory Antivirals Consumption Value by Application (2019-2030)
7.3 Europe Respiratory Antivirals 麻豆原创 Size by Country
7.3.1 Europe Respiratory Antivirals Consumption Value by Country (2019-2030)
7.3.2 Germany Respiratory Antivirals 麻豆原创 Size and Forecast (2019-2030)
7.3.3 France Respiratory Antivirals 麻豆原创 Size and Forecast (2019-2030)
7.3.4 United Kingdom Respiratory Antivirals 麻豆原创 Size and Forecast (2019-2030)
7.3.5 Russia Respiratory Antivirals 麻豆原创 Size and Forecast (2019-2030)
7.3.6 Italy Respiratory Antivirals 麻豆原创 Size and Forecast (2019-2030)
8 Asia-Pacific
8.1 Asia-Pacific Respiratory Antivirals Consumption Value by Type (2019-2030)
8.2 Asia-Pacific Respiratory Antivirals Consumption Value by Application (2019-2030)
8.3 Asia-Pacific Respiratory Antivirals 麻豆原创 Size by Region
8.3.1 Asia-Pacific Respiratory Antivirals Consumption Value by Region (2019-2030)
8.3.2 China Respiratory Antivirals 麻豆原创 Size and Forecast (2019-2030)
8.3.3 Japan Respiratory Antivirals 麻豆原创 Size and Forecast (2019-2030)
8.3.4 South Korea Respiratory Antivirals 麻豆原创 Size and Forecast (2019-2030)
8.3.5 India Respiratory Antivirals 麻豆原创 Size and Forecast (2019-2030)
8.3.6 Southeast Asia Respiratory Antivirals 麻豆原创 Size and Forecast (2019-2030)
8.3.7 Australia Respiratory Antivirals 麻豆原创 Size and Forecast (2019-2030)
9 South America
9.1 South America Respiratory Antivirals Consumption Value by Type (2019-2030)
9.2 South America Respiratory Antivirals Consumption Value by Application (2019-2030)
9.3 South America Respiratory Antivirals 麻豆原创 Size by Country
9.3.1 South America Respiratory Antivirals Consumption Value by Country (2019-2030)
9.3.2 Brazil Respiratory Antivirals 麻豆原创 Size and Forecast (2019-2030)
9.3.3 Argentina Respiratory Antivirals 麻豆原创 Size and Forecast (2019-2030)
10 Middle East & Africa
10.1 Middle East & Africa Respiratory Antivirals Consumption Value by Type (2019-2030)
10.2 Middle East & Africa Respiratory Antivirals Consumption Value by Application (2019-2030)
10.3 Middle East & Africa Respiratory Antivirals 麻豆原创 Size by Country
10.3.1 Middle East & Africa Respiratory Antivirals Consumption Value by Country (2019-2030)
10.3.2 Turkey Respiratory Antivirals 麻豆原创 Size and Forecast (2019-2030)
10.3.3 Saudi Arabia Respiratory Antivirals 麻豆原创 Size and Forecast (2019-2030)
10.3.4 UAE Respiratory Antivirals 麻豆原创 Size and Forecast (2019-2030)
11 麻豆原创 Dynamics
11.1 Respiratory Antivirals 麻豆原创 Drivers
11.2 Respiratory Antivirals 麻豆原创 Restraints
11.3 Respiratory Antivirals Trends Analysis
11.4 Porters Five Forces Analysis
11.4.1 Threat of New Entrants
11.4.2 Bargaining Power of Suppliers
11.4.3 Bargaining Power of Buyers
11.4.4 Threat of Substitutes
11.4.5 Competitive Rivalry
12 Industry Chain Analysis
12.1 Respiratory Antivirals Industry Chain
12.2 Respiratory Antivirals Upstream Analysis
12.3 Respiratory Antivirals Midstream Analysis
12.4 Respiratory Antivirals Downstream Analysis
13 Research Findings and Conclusion
14 Appendix
14.1 Methodology
14.2 Research Process and Data Source
14.3 Disclaimer

Companies Mentioned:

GSK
Boehringer Ingelheim
AstraZeneca
Merck
Novartis
Beximco Pharmaceuticals
Pfizer
Roche
Bristol-Myers Squibb Company
Johnson & Johnson
AbbVie Inc.
Sanofi

License Types:

Single User License (PDF)

This license allows for use of a publication by one person.
This person may print out a single copy of the publication.
This person can include information given in the publication in presentations and internal reports by providing full copyright credit to the publisher.
This person cannot share the publication (or any information contained therein) with any other person or persons.
Unless a Enterprise License is purchased, a Single User License must be purchased for every person that wishes to use the publication within the same organization.
Customers who infringe these license terms are liable for a Global license fee.

听

Site License (PDF)*

This license allows for use of a publication by all users within one corporate location, e.g. a regional office.
These users may print out a single copy of the publication.
These users can include information given in the publication in presentations and internal reports by providing full copyright credit to the publisher.
These users cannot share the publication (or any information contained therein) with any other person or persons outside the corporate location for which the publication is purchased.
Unless a Enterprise License is purchased, a Site User License must be purchased for every corporate location by an organization that wishes to use the publication within the same organization.
Customers who infringe these license terms are liable for a Global license fee.

听

Global License (PDF)*

This license allows for use of a publication by unlimited users within the purchasing organization e.g. all employees of a single company.
Each of these people may use the publication on any computer, and may print out the report, but may not share the publication (or any information contained therein) with any other person or persons outside of the organization.
These employees of purchasing organization can include information given in the publication in presentations and internal reports by providing full copyright credit to the publisher.

*If Applicable.